Daiichi Sankyo and AstraZeneca's ENHERTU has been conditionally approved by China's NMPA for a specific type of NSCLC.

Inventiva will gain a new chairman following the deal as it presses ahead with a Phase III trial for its lead asset.

Capricor Therapeutics plans to apply for FDA approval for its DMD cell therapy, deramiocel, by the end of 2024.

Sanofi has announced negotiations with Clayton Dubilier & Rice (CD&R), regarding the potential sale of a 50% controlling ...

Pfizer has announced the approval of HYMPAVZI by the US Food and Drug Administration (FDA) for patients with haemophilia A ...

Trends in gene therapy approvals in recent years are rapidly shaping the future of manufacturing capabilities in the ...

RHEACELL has been researching ABCB5-positive stem cell therapies for patients with severe immune and inflammation-related ...

KeyBioscience and Eli Lilly have extended their partnership to develop a new class of treatments for obesity and associated ...

Imuldosa is the latest FDA-approved biosimilar of J&J’s blockbuster therapy for the treatment of certain autoimmune diseases.

The Cardiovascular and Renal Drugs Advisory Committee voted 10-6 in support of Stealth’s elamipretide for the ultra-rare ...

The deal allows MSD to license one or more therapies against inflammatory diseases developed using the UK biotech’s ...